YoungSukOhMDMS

Gastroenterology • Palo Alto, CA

Advanced Endoscopic Interventional, Biliary Tract Disease, Inflammatory Bowel Disease, Pancreas Disease

Executive Director, Gastroenterology Clinical Team Lead Bristol Myers Squibb

Join to view full profile

Dr. Oh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oh's full profile

Already have an account?

Office
3801 Miranda Ave
Palo Alto, CA 94304

Education & Training

Medical College of WisconsinMS, Clinical and Translational Science, 2010 - 2014
University of Pennsylvania Health SystemFellowship, Gastroenterology, 2006 - 2007
Washington University/B-JH/SLCH ConsortiumFellowship, Gastroenterology, 2003 - 2006
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2001 - 2003
Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 2000 - 2001
University of Texas Southwestern Medical SchoolClass of 2000
University of MichiganBSE, Chemical Engineering, 1992 - 1996

Certifications & Licensure

WI State Medical License 2009 - 2025
CA State Medical License 2015 - 2024
WA State Medical License 2007 - 2009
PA State Medical License 2006 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Publications & Presentations

PubMed

53 citations
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, ran...
Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie D. Long, Matthieu Allez
The Lancet. Gastroenterology & Hepatology. 2021-11-17
39 citations
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3...
Severine Vermeire, Peter L. Lakatos, Timothy Ritter, Stephen B. Hanauer, Brian Bressler
The Lancet. Gastroenterology & Hepatology. 2021-11-16
47 citations
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Silvio Danese, Jean-Frederic Colombel, Milan Lukas, Javier P Gisbert, Geert R. D'Haens
The Lancet. Gastroenterology & Hepatology. 2021-11-16

Committees

Member, Membership and Diversity Committee, American Society for Gastrointestinal Endoscopy 2015 - Present
Member, Publications Committee, American College of Gastroenterology 2013 - Present
Member, Editorial Board, Gastrointestinal Endoscopy 2011 - 2015

Professional Memberships

Industry Relationships

Consultant, Boston Scientific Corporation2011 - 2012